Moderna Cancer Vaccine Breakthrough Sparks $144 Stock Surge

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Tuesday morning, building on their impressive 150% surge over the trailing month.

The catalyst driving Moderna's stock higher is its Phase 3 clinical data for intismeran autogene (mRNA-4157), a personalized cancer vaccine developed with Merck. The trial met its primary endpoints, demonstrating that mRNA-4157 combined with Keytruda significantly reduced the risk of recurrence and distant metastasis in high-risk melanoma patients post-resection.

This breakthrough serves as validation for Moderna's therapeutic mRNA platform beyond respiratory viruses, opening up multi-billion-dollar addressable oncology markets. The successful Phase 3 readout has also shifted investor focus to upcoming regulatory submissions.